517 related articles for article (PubMed ID: 17335844)
21. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
22. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection.
Oliver B; Orpez T; Mayorga C; Pinto-Medel MJ; Leyva L; López-Gómez C; Marín C; Luque G; Ortega-Pinazo J; Fernández O
J Immunol Methods; 2009 Dec; 351(1-2):41-5. PubMed ID: 19786034
[TBL] [Abstract][Full Text] [Related]
24. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
Vartanian T; Sölberg Sørensen P; Rice G
J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
[TBL] [Abstract][Full Text] [Related]
25. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
26. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
28. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
29. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
31. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
Lapé Nixon M; Matud J; Yeh C; Prince HE
J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
[TBL] [Abstract][Full Text] [Related]
35. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
36. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
Pachner A; Narayan K; Price N; Hurd M; Dail D
Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
[TBL] [Abstract][Full Text] [Related]
38. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.
Bertolotto A; Gilli F; Sala A; Audano L; Castello A; Magliola U; Melis F; Giordana MT
J Immunol Methods; 2001 Oct; 256(1-2):141-52. PubMed ID: 11516761
[TBL] [Abstract][Full Text] [Related]
40. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
Gilli F; De La Torre AL; Royce DB; Pachner AR
Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]